Medicenna's MDNA11 Potential in Earlier Line Melanoma Setting Highlighted in Presentation of the NEO-CYT trial at ASCO 2026

About this update from Medicenna Therapeutics Corp.

Medicenna’s MDNA11 Potential in Earlier Line Melanoma Setting Highlighted in Presentation of the NEO-CYT trial at ASCO 2026 NEO-CYT positions MDNA11 in a frontline neoadjuvant melanoma setting, where immunotherapy before surgery may help generate deeper and more durable anti-tumor immune responses  Up to 80 patients with locally advanced melanoma will be randomized in this Investigator-sponsored, multicenter Phase 1b NEO-CYT trial led by Professor Paolo A. Ascierto of the Istituto Nazionale Tumori Fondazione “G. Pascale” and sponsored by Fondazione Melanoma Onlus Together with the ongoing Phase 1/2 ABILITY-1 expansion cohorts in the 2L/3L Tx setting, NEO-CYT supports a broader clinical strategy to evaluate MDNA11 across select tumor types and multiple stages of disease, expanding future commercial opportunities MDNA11 clinical data updates from the ABILITY-1 and NEO-CYT trials are anticipated in H2 2026 TORONTO and HOUSTON, June 03, 2026 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQX: MDNAF), a clinical-stage immunotherapy company developing Superkines targeting cancer and autoimmune disease, today announced that its long-acting, “beta-enhanced not-alpha” IL-2 Superkine, MDNA11, was featured in a poster presentation describing the investigator-sponsored NEO-CYT trial at the 2026 Annual Meeting of the American Society of Clinical Oncology (ASCO), held in Chicago from 28th May to 2nd June. Surgery has long been the first course of action in treating locally advanced melanoma. Recently, the landmark NADINA clinical trial (comprised of 2 pre-operative cycles of ipilimumab plus nivolumab) completely flipped the conventional treatment paradigm on its head by proving that giving combination immunotherapy before surgery is significantly more effective than the previous post-surgery standard, setting a new gold standard of care. However even with this regimen, 41% of patients did not achieve a Major Pathologic Response (< 10% of viable tumor). In view of the promising single agent activity of MDNA11 in patients with metastatic melanoma, the hypothesis of the NEO-CYT trial is to demonstrate if patient outcomes can be further enhanced over the gold-standard of care by introducing MDNA11 in combination with nivolumab +/- ipilimumab. “NEO-CY...

View stock analysis, news, and events for Medicenna Therapeutics Corp.